New Spacer From Artimplant Receives CE-mark.
STOCKHOLM, Sweden -- The biomaterials company Artimplant (STO:ARTIB), has received CE mark for its Artelon(R) DRU DRU Druid (Everquest)
DRU Disaster Resistant University
DRU Direct Reporting Unit
DRU Dansk Rugby Union (Danish Rugby Club)
DRU Dynamic Reference Unit
DRU Data Recovery Unit
DRU Data Retrieval Unit Spacer.
The spacer is intended for treatment of osteoarthritis osteoarthritis
or osteoarthrosis or degenerative joint disease
Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. in the distal radioulnar (DRU) joint of the wrist.
This is one of four products under the recent development and license agreements with Small Bone innovations, LLC (Logical Link Control) See "LANs" under data link protocol.
LLC - Logical Link Control (SBI SBI Special Background Investigation
SBI Subsidiary Body for Implementation
SBI State Bank of India
SBI Secure Border Initiative
SBI Small Business Institute
SBI Stockholm Brain Institute
SBI Serious Bacterial Infection
SBI Society of Breast Imaging ).
Osteoarthritis in the distal radioulnar joint of the wrist
Fractures in the wrist region often results in complications. One of them could be osteoarthritis (OA) in the joint surface between distal radius and ulna ulna: see arm. . OA of the DRU joint often leads to ulnar ulnar /ul·nar/ (ul´ner) pertaining to the ulna or to the ulnar (medial) aspect of the arm as compared to the radial (lateral) aspect. wrist pain, limitation of forearm rotation and reduced grip strength, all of which limit activities of daily living. With Artelon(R) DRU Spacer the forearm will function in a natural way.
The field of application for Artelon(R) DRU Spacer is relatively limited and today the number of surgeries is estimated to about 3 000 annually on a global basis.
Artelon(R) - a unique biomaterial
Artelon(R) DRU Spacer is made of Artelon(R), a unique long-term degradable de·grad·a·ble
That can be chemically degraded: degradable plastic wastes.
de·grad biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility biocompatibility
the quality of not having toxic or injurious effects on biological systems.
biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. in hard and soft tissue - Artelon(R) offers new solutions to unmet clinical needs in several therapy areas.
Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements and one distribution agreement with three global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863  it is the primary securities exchange of the Nordic Countries. , O-list.
Small Bone Innovations, LLC (SBI) was founded in 2004 by Viscogliosi Bros., LLC, (VB), the New York-based merchant banking firm that specializes in the musculoskeletal musculoskeletal /mus·cu·lo·skel·e·tal/ (-skel´e-t'l) pertaining to or comprising the skeleton and muscles.
Relating to or involving the muscles and the skeleton. /orthopedic sector. VB created SBI as the first company to focus purely on small bone & joint science. By integrating established companies and professionals in the field, SBI today offers a broad , clinically proven portfolio of products and technology to treat trauma and diseases in small bones & joints.
VB's acquisitions and technology licenses include: Avanta Orthopaedics, Inc. (finger/hand/wrist/elbow arthroplasty and trauma products - USA); Envision Manufacturing, Inc.(implant manufacturing - USA); Actipore (TM) (porous metal technology - Canada); Artelon (R)(biologically active & biodegradable technology - Sweden); Xtremi-T, LLC (bioabsorbable trauma technology - USA); and Fixano, S.A.S. (broad line of small bone & joint implants - France).
For more information, visit: www.totalsmallbone.com
About Viscogliosi Bros., LLC
Established by Marc R. Viscogliosi, John J. Viscogliosi and Anthony G. Viscogliosi in New York City New York City: see New York, city.
New York City
City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. in 1999, VB was the first venture capital/private equity and merchant banking firm dedicated to the musculoskeletal/orthopedics sector of the health care industry. Today, VB is a leading independent firm with a mission to create, build and finance companies founded on innovations developed by surgeons and uniquely focused on "life changing" musculoskeletal/orthopedic technologies. VB has worldwide surgeon, industry and trade relationships and significant financial expertise in the musculoskeletal/orthopedic sector.
As principals of VB, the Viscogliosi brothers have a combined total of more than 35 years experience analyzing and investing in the musculoskeletal/orthopedics sector. They have pioneered innovative financial, strategic and management initiatives for companies in the sector, from start-up, seed and development stage all the way to exit, while helping thousands of people lead better lives through the orthopedic and spinal products marketed and sold by the companies they have assisted in financing and developing.
For more information visit: www.vbllc.com
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence ob·so·les·cent
1. Being in the process of passing out of use or usefulness; becoming obsolete.
2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed from time to time in the Company's filings.
This information was brought to you by Waymaker http://www.waymaker.net